These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22093142)

  • 1. Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes--the ADDITION-Netherlands study: a cluster-randomized trial.
    Koekkoek PS; Ruis C; van den Donk M; Biessels GJ; Gorter KJ; Kappelle LJ; Rutten GE
    J Neurol Sci; 2012 Mar; 314(1-2):71-7. PubMed ID: 22093142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial.
    Griffin SJ; Rutten GEHM; Khunti K; Witte DR; Lauritzen T; Sharp SJ; Dalsgaard EM; Davies MJ; Irving GJ; Vos RC; Webb DR; Wareham NJ; Sandbæk A
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):925-937. PubMed ID: 31748169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes as a risk factor for cognitive decline in older patients.
    Maggi S; Limongi F; Noale M; Romanato G; Tonin P; Rozzini R; Scafato E; Crepaldi G;
    Dement Geriatr Cogn Disord; 2009; 27(1):24-33. PubMed ID: 19088471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus.
    van den Berg E; Reijmer YD; de Bresser J; Kessels RP; Kappelle LJ; Biessels GJ;
    Diabetologia; 2010 Jan; 53(1):58-65. PubMed ID: 19882137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive function and information processing in type 2 diabetes.
    Cosway R; Strachan MW; Dougall A; Frier BM; Deary IJ
    Diabet Med; 2001 Oct; 18(10):803-10. PubMed ID: 11678970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognition in the early stage of type 2 diabetes.
    Ruis C; Biessels GJ; Gorter KJ; van den Donk M; Kappelle LJ; Rutten GE
    Diabetes Care; 2009 Jul; 32(7):1261-5. PubMed ID: 19366968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of intensive multifactorial treatment on perceptions of chronic care among individuals with screen-detected diabetes: results from the ADDITION-Denmark trial.
    Kuznetsov L; Simmons RK; Sandbaek A; Maindal HT
    Int J Clin Pract; 2015 Apr; 69(4):466-73. PubMed ID: 25382351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function.
    Awad N; Gagnon M; Messier C
    J Clin Exp Neuropsychol; 2004 Nov; 26(8):1044-80. PubMed ID: 15590460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study.
    Sandbæk A; Griffin SJ; Sharp SJ; Simmons RK; Borch-Johnsen K; Rutten GE; van den Donk M; Wareham NJ; Lauritzen T; Davies MJ; Khunti K
    Diabetes Care; 2014 Jul; 37(7):2015-23. PubMed ID: 24784827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ADDITION-Cambridge trial protocol: a cluster -- randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients.
    Echouffo-Tcheugui JB; Simmons RK; Williams KM; Barling RS; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
    BMC Public Health; 2009 May; 9():136. PubMed ID: 19435491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results From a Feasibility Study of Square-Stepping Exercise in Older Adults With Type 2 Diabetes and Self-Reported Cognitive Complaints to Improve Global Cognitive Functioning.
    Shellington EM; Reichert SM; Heath M; Gill DP; Shigematsu R; Petrella RJ
    Can J Diabetes; 2018 Dec; 42(6):603-612.e1. PubMed ID: 29884522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes after 10-year follow-up of intensive, multifactorial treatment in individuals with screen-detected type 2 diabetes: the ADDITION-Europe trial.
    Dalsgaard EM; Sandbaek A; Griffin SJ; Rutten GEHM; Khunti K; Davies MJ; Irving GJ; Vos RC; Webb DR; Wareham NJ; Witte DR
    Diabet Med; 2020 Sep; 37(9):1509-1518. PubMed ID: 32530523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial.
    Simmons RK; Sharp SJ; Sandbæk A; Borch-Johnsen K; Davies MJ; Khunti K; Lauritzen T; Rutten GE; van den Donk M; Wareham NJ; Griffin SJ
    Diabet Med; 2012 Nov; 29(11):e409-16. PubMed ID: 22823477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing covariates of Type 2 diabetes-cognition associations in older adults: moderating or mediating effects?
    McFall GP; Geall BP; Fischer AL; Dolcos S; Dixon RA
    Neuropsychology; 2010 Sep; 24(5):547-562. PubMed ID: 20804243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe hypoglycaemia and late-life cognitive ability in older people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.
    Aung PP; Strachan MW; Frier BM; Butcher I; Deary IJ; Price JF;
    Diabet Med; 2012 Mar; 29(3):328-36. PubMed ID: 22023662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial.
    Sullivan MD; Katon WJ; Lovato LC; Miller ME; Murray AM; Horowitz KR; Bryan RN; Gerstein HC; Marcovina S; Akpunonu BE; Johnson J; Yale JF; Williamson J; Launer LJ
    JAMA Psychiatry; 2013 Oct; 70(10):1041-7. PubMed ID: 23945905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.
    Griffin SJ; Borch-Johnsen K; Davies MJ; Khunti K; Rutten GE; Sandbæk A; Sharp SJ; Simmons RK; van den Donk M; Wareham NJ; Lauritzen T
    Lancet; 2011 Jul; 378(9786):156-67. PubMed ID: 21705063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of six years intensified multifactorial treatment on levels of hs-CRP and adiponectin in patients with screen detected type 2 diabetes: the ADDITION-Netherlands randomized trial.
    den Ouden H; Berends J; Stellato RK; Beulens JW; Rutten GE
    Diabetes Metab Res Rev; 2015 Oct; 31(7):758-66. PubMed ID: 26109470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haptoglobin genotype modulates the relationships of glycaemic control with cognitive function in elderly individuals with type 2 diabetes.
    Guerrero-Berroa E; Ravona-Springer R; Heymann A; Schmeidler J; Levy A; Leroith D; Beeri MS
    Diabetologia; 2015 Apr; 58(4):736-44. PubMed ID: 25628235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control.
    West RK; Ravona-Springer R; Schmeidler J; Leroith D; Koifman K; Guerrero-Berroa E; Preiss R; Hoffman H; Silverman JM; Heymann A; Schnaider-Beeri M
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):1055-9. PubMed ID: 24534521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.